These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1026071)

  • 21. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
    Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
    Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study.
    Tan YO; Hendrickson C; McWhirter K; Kohler M; Hannigan JF; Carlson RW
    Cancer Treat Rep; 1987 Oct; 71(10):969-70. PubMed ID: 2958131
    [No Abstract]   [Full Text] [Related]  

  • 23. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
    Tomic R; Ljungberg B; Damber JE
    Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of prostatic adenoma with medroxyprogesterone acetate].
    Maltoni G; Zoli M
    Minerva Urol; 1972; 24(5):184-99. PubMed ID: 4141051
    [No Abstract]   [Full Text] [Related]  

  • 25. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
    Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
    Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
    [No Abstract]   [Full Text] [Related]  

  • 26. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 27. [Study on etoposide therapy of relapsing prostatic cancer patients].
    Moriyama M; Murai T; Kondoh I
    Hinyokika Kiyo; 1990 Jul; 36(7):777-81. PubMed ID: 2239575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial.
    Moore MR; Graham SD; Birch R; Irwin L
    Cancer Treat Rep; 1987 Jan; 71(1):89-90. PubMed ID: 3791273
    [No Abstract]   [Full Text] [Related]  

  • 30. [Medical treatment of malignant bone tumors (carcinolytics, hormonotherapy, immunotherapy)].
    Clavel B
    Sem Hop; 1974 Jan; 50(4):287-95. PubMed ID: 4368180
    [No Abstract]   [Full Text] [Related]  

  • 31. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
    Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
    Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Overall evaluation of the results of treatment of metastatic carcinomas of the breast with high doses of MAP combined with bromocryptin].
    Mussa A; Dogliotti L; Di Carlo F
    Minerva Med; 1980 Feb; 71(6):391-400. PubMed ID: 7360379
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.
    Moore MR; Troner MB; DeSimone P; Birch R; Irwin L
    Cancer Treat Rep; 1986 Apr; 70(4):541-2. PubMed ID: 3698053
    [No Abstract]   [Full Text] [Related]  

  • 34. Hormone therapy in prostatic cancer.
    Smith PH; Akdas A; Mason MK; Richards B; Robinson MR; de Pauw M; Sylvester R
    Acta Urol Belg; 1980 Jan; 48(1):98-105. PubMed ID: 7001876
    [No Abstract]   [Full Text] [Related]  

  • 35. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
    Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
    Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of progestational agents in the management of metastatic carcinoma of the endometrium.
    Kistner RW; Griffiths CT
    Clin Obstet Gynecol; 1968 Jun; 11(2):439-56. PubMed ID: 4879374
    [No Abstract]   [Full Text] [Related]  

  • 37. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
    Rusakov IG; Alekseev BIa
    Urologiia; 2002; (5):23-6. PubMed ID: 12402771
    [No Abstract]   [Full Text] [Related]  

  • 38. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The evaluation of chemotherapy of relapse in prostatic cancer with new response criteria].
    Isaka S; Fuse H; Akaza H; Moriyama N; Usami M; Kotake T; Matsumura Y; Imai K; Yamanaka H; Matsumoto K
    Hinyokika Kiyo; 1987 Sep; 33(9):1389-95. PubMed ID: 3434494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
    Drelichman A; Brownlee R; Al-Sarraf M
    Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.